Zydus gets nod to conduct Phase II clinical study in patients with CAPS in Australia
newsdepo.com
The company has received permission to initiate the Phase II clinical study of its NLRP3 inhibitor âZYIL1â in patients with CAPS in Australia.Zydus gets nod to conduct Phase II clinical study in patients with CAPS in Australia
The company has received permission to initiate the Phase II clinical study of its NLRP3 inhibitor âZYIL1â in patients with CAPS in Australia. Read more